Clinical Trials
Advanced Vision Research Institute
Since the Eye Care Center of Northern Colorado opened in 1969, our practitioners have been interested in the advancement of science and focused on offering the best patient care possible for all ocular conditions. We are now proud to announce the opening of Advanced Vision Research Institute. We are actively participating in clinical trials and providing access to medications and cutting-edge devices that would otherwise be unavailable to our patients.
Current Clinical Trials
NAAVIGATE
Protocol: M23-415
Sponsor: AbbVie Inc.
An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered Via Suprachoroidal Space (SCS) Injection Targeting Subjects With Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (CI-DME) (NAAVIGATE)
Indication: Diabetic Retinopathy
ClinicalTrials.gov Identifier: NCT07592273
ACHIEVE
Protocol: M24-528
Sponsor: AbbVie Inc.
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
Indication: Neovascular (wet) age-related macular degeneration (wet AMD)
ClinicalTrials.gov Identifier: NCT07007065
SIENNA
Protocol: R3918-AMD-2326
Sponsor: Regeneron Pharmaceuticals, Inc.
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Indication: Geographic Atrophy (GA)
ClinicalTrials.gov Identifier: NCT06541704
GALLOP
Protocol: APL3007-GA-201
Sponsor: Apellis Pharmaceuticals, Inc.
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with SYFOVRE/pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Indication: Geographic Atrophy (GA)
ClinicalTrials.gov Identifier: NCT07215390
Closed Clinical Trials
SEER-2
Protocol: RGN-NK-302
Sponsor: ReGenTree, LLC
A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)
Indication: Neurotrophic Keratopathy
ClinicalTrials.gov Identifier: NCT05555589
Belvedere
Protocol: ML43000
Sponsor: F. Hoffmann-La Roche Ltd.
Indication: Neovascular (wet) age-related macular degeneration (wet AMD)
ClinicalTrials.gov Identifier: NCT04853251
Ascent
Protocol: RGX-314-3101
Sponsor: AbbVie
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Indication: Neovascular (wet) age-related macular degeneration (wet AMD)
ClinicalTrials.gov Identifier: NCT05407636
DIAMOND2
Protocol: DX221
Sponsor: Oculis Operations Sàrl
Indication: Diabetic Macular Edema (DME)
ClinicalTrials.gov Identifier: NCT06172257
GO-1
Protocol: IMVT-1401-3201
Sponsor: Immunovant Sciences GmbH
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
Indication: Active moderate to severe thyroid eye disease (TED)
ClinicalTrials.gov Identifier: NCT05517421
Alexion / ALXN2040-GA-201
ClinicalTrials.gov Identifier: NCT05019521
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This Study is currently closed for enrollment with patients remaining in followup care.
Unity / UBX1325-02
ClinicalTrials.gov Identifier: NCT04857996
This is a Phase 2a Proof-of-Concept (POC) study. The study has enrolled approximately 62 patients that were randomized 1:1 into either the UBX1325 or sham study arms, in order to assess the primary objective(s). All patients are in a 24-week follow-up period.
This Study is currently closed for enrollment with patients remaining in followup care.
Olympia / OPP-102
ClinicalTrials.gov Identifier: NCT04957758
A Phase 2, Multicenter, Randomized, Controlled, Double Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (varenicline) Nasal Spray in Subjects with Neurotrophic Keratopathy (the Olympia Study)
This Study is currently closed for enrollment with patients remaining in followup care.
Unity / UBX1325-03
Clinicaltrials.gov ID: NCT05275205
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration (wet AMD)
This Study is currently closed for enrollment with patients remaining in followup care.
ShORe
Protocol: OPT-302-1004
Sponsor: Opthea Limited
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Indication: Neovascular (wet) age-related macular degeneration (wet AMD)
ClinicalTrials.gov Identifier: NCT04757610
HONU
Protocol: GE43220
Sponsor: Genentech, Inc.
A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Indication: Age-Related Macular Degeneration
ClinicalTrials.gov Identifier: NCT05300724
ASPIRE
Protocol: UBX1325-04
Sponsor: Unity Biotechnology, Inc.
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema
Indication: Diabetic Macular Edema
ClinicalTrials.gov Identifier: NCT06011798
SatraGo-2
Sponsor: F. Hoffmann-La Roche Ltd.
Indication: Active Moderate-to-Severe Thyroid Eye Disease (TED)
ClinicalTrials.gov Identifier: NCT06106828
LUGANO
Protocol: EYP-1901-301
Sponsor: EyePoint Pharmaceuticals, Inc.
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
Indication: Neovascular (wet) age-related macular degeneration (wet AMD)
ClinicalTrials.gov Identifier: NCT06668064
THAMES
Protocol: GR43828
Sponsor: Genentech, Inc.
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination with Aflibercept or Faricimab in Patients with Diabetic Macular Edema
Indication: Diabetic Macular Edema (DME)
ClinicalTrials.gov Identifier: NCT06850922
GOCS-H101-E06
Protocol: GOCS-H101-E06
Sponsor: Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
Indication: Age-Related Cataract
ClinicalTrials.gov Identifier: NCT07395986
ELARA
Protocol Number: VGFTe-HD-OD-2444
Sponsor: Regeneron Pharmaceuticals, Inc.
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Indication: Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ClinicalTrials.gov Identifier: NCT06491914
Public Notices
IBC Meeting Minites
Clinical Trial FAQ's
Do you offer patient clinical trial options?
Yes, since the Eye Care Center of Northern Colorado opened in 1969, our practitioners have been interested in the advancement of science and focused on offering the best patient care possible for all ocular conditions.We are actively participating in clinical trials and providing access to medications and cutting-edge devices that would otherwise be unavailable to our patients. Check out our website for more information.
